Acquired PIK3CA amplification causes resistance to selective phosphoinositide 3-kinase inhibitors in breast cancerL-Y Huw, Mark R. Lackner|Oncogenesis|2013Cited by 89
Targeted Biomarker Profiling of Matched Primary and Metastatic Estrogen Receptor Positive Breast CancersErica Schleifman, Mark R. Lackner|PLoS ONE|2014Cited by 36
Cyclin E1/CDK2 activation defines a key vulnerability to WEE1 kinase inhibition in gynecological cancersDaehwan Kim, Mark R. Lackner|npj Precision Oncology|2025Cited by 15